Agenus Inc. (AGEN) stock is falling over 14 percent on Friday morning after the announcement of updated data from its phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic colorectal cancer, that is not microsatellite instability-high or MSS, or deficient mismatch repair or dMMR.